staurosporine has been researched along with 7-hydroxystaurosporine in 300 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (1.67) | 18.7374 |
| 1990's | 59 (19.67) | 18.2507 |
| 2000's | 176 (58.67) | 29.6817 |
| 2010's | 54 (18.00) | 24.3611 |
| 2020's | 6 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bower, MJ; Concha, NO; Davis, ST; Green, SM; Johanson, KO; McDevitt, PJ; Zhao, B; Zhao, H; Zhou, BB | 1 |
| Alessi, DR; Bain, J; Elliott, M; Komander, D; Kular, GS; Van Aalten, DM | 1 |
| Hayashi, T; Kato, H; Koshino, Y; Kutsumi, Y; Miyabo, S; Nakai, T | 1 |
| Nakano, H; Tamaoki, T | 1 |
| Tamaoki, T | 1 |
| Akinaga, S; Gomi, K; Morimoto, M; Okabe, M; Tamaoki, T | 1 |
| Kobayashi, E; Murakata, C; Nakano, H; Saitoh, H; Suzuki, K; Takahashi, I; Tamaoki, T | 1 |
| Hamamoto, Y; Hayashida, Y; Kobayashi, N; Kobayashi, S; Tamaoki, T; Yamamoto, N | 1 |
| Morimoto, M; Nakano, H; Saitoh, Y; Sano, H; Takahashi, I; Tamaoki, T; Yoshida, M | 1 |
| Burgess, GM; Rüegg, UT | 1 |
| Asano, K; Kawamoto, I; Nakano, H; Takahashi, I; Tamaoki, T | 1 |
| Asano, K; Kobayashi, E; Nakano, H; Takahashi, I; Yoshida, M | 1 |
| Akinaga, S; Gomi, K; Nomura, K; Okabe, M | 2 |
| Blume, E | 1 |
| Fujiwara, R; Miyabo, S; Nakai, T; Shimada, A; Tamai, T | 1 |
| Endo, K; Takei, M | 1 |
| Kaur, G; Sausville, EA; Sebers, S; Seynaeve, CM; Stetler-Stevenson, M; Worland, PJ | 1 |
| Budworth, J; Courage, C; Gescher, A | 1 |
| Hanaki, H; Hirai, S; Ikuta, T; Kuroki, T; Mizuno, K; Noda, K; Osada, S; Saido, TC; Tamaoki, T; Ueda, Y | 1 |
| Hill, DL; Posey, CF; Rose, LM; Tillery, KF | 1 |
| Blumberg, PM; Kazanietz, MG; Sausville, EA; Seynaeve, CM; Worland, PJ | 1 |
| Mizuno, K; Ohno, S; Saido, TC; Suzuki, K; Tamaoki, T | 1 |
| Carlson, BA; Clark, JL; Sausville, EA; Wang, Q; Worland, PJ | 1 |
| Budworth, J; Davies, R; Ferry, DR; Gant, TW; Gescher, A; Malkhandi, J | 1 |
| Futami, H; Kawakami, K; Takahara, J; Yamaguchi, K | 1 |
| Eastman, A; Fan, S; O'Connor, PM; Sausville, EA; Wang, Q; Worland, PJ | 1 |
| Pommier, Y; Shao, RG; Shimizu, T | 2 |
| Akinaga, S; Akiyama, T; Mizukami, T; Okabe, M; Shimizu, M; Tsujita, T; Yoshida, T | 1 |
| Bunch, RT; Eastman, A | 2 |
| Courage, C; Gescher, A; Hubbard, A; Jones, T | 1 |
| Cao, CX; Kohn, KW; O'Connor, PM; Pommier, Y; Shao, RG; Shimizu, T | 1 |
| Tsuchida, E; Urano, M | 1 |
| Cao, CX; Pommier, Y; Shao, RG | 2 |
| Bartimole, TM; Dent, P; Freemerman, AJ; Grant, S; Jarvis, WD; Kramer, LB; Krystal, G; Vrana, JA; Wang, S | 1 |
| Bradder, SM; Courage, C; Gescher, A; Jones, T; Schultze-Mosgau, MH | 1 |
| Saijo, N | 1 |
| Byrd, JC; Grever, MR; Rai, KR; Sausville, EA | 1 |
| Fuse, E; Kobayashi, H; Kobayashi, S; Kuramitsu, T; Kurata, N; Kuwabara, T; Tanii, H | 1 |
| Akinaga, S; Arbuck, SG; Figg, WD; Fuse, E; Headlee, D; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Lush, RD; Sasaki, Y; Sausville, EA; Senderowicz, AM; Shimada, Y; Tamura, T; Tanigawara, Y; Tanii, H | 1 |
| Hsueh, CT; Kelsen, D; Schwartz, GK | 1 |
| Arbuck, SG; Figg, WD; Fuse, E; Headlee, D; Kobayashi, S; Kuwabara, T; Lush, RD; Sausville, EA; Senderowicz, AM; Smith, AC; Tanii, H | 1 |
| Cohen, GM; Gescher, A; Harkin, ST | 1 |
| Alfieri, AA; Sommers, GM | 1 |
| Gescher, A | 2 |
| Aghajanian, C; Husain, A; Rosales, N; Schwartz, GK; Spriggs, DR; Yan, XJ | 1 |
| Chanock, SJ; Hiraoka, W; Nieves-Neira, W; Pommier, Y; Vazquez, N | 1 |
| O'Connor, PM; Orlandi, L; Orr, MS; Piwnica-Worms, H; Sausville, EA; Senderowicz, AM; Silvestrini, R; Wang, P; Watanabe, N; Yu, L | 1 |
| Cao, CX; Kohn, KW; Pommier, Y; Shao, RG; Wold, MS; Zhang, H | 1 |
| Asanome, K; Fuse, E; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Sugiyama, Y; Takai, K; Tanii, H | 1 |
| Akinaga, S; Akiyama, T; Okabe, M; Shimizu, M; Tamaoki, T | 1 |
| Bredel, M; Freund, JM; Lazo, JS; Pollack, IF; Rusnak, J | 1 |
| Aono, S; Nakagawa, S; Reynolds, AB; Takeichi, M | 1 |
| Akinaga, S; Akiyama, T; Fuse, E; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Tanii, H; Yamaguchi, K | 1 |
| Nieves-Neira, W; Pommier, Y | 1 |
| Akinaga, S; Akiyama, T; Courage, C; Gescher, A; Shimizu, M; Sugiyama, K; Tamaoki, T | 1 |
| Jiang, H; Yang, LY | 1 |
| Bowen, C; Edelman, MJ; Gandara, DR; Gelmann, EP; Gumerlock, PH; Mack, PC; Paglieroni, T; Schnier, JB | 1 |
| Brown, MK; Eastman, A; Lee, SI | 1 |
| Chen, X; Keyomarsi, K; Lowe, M | 1 |
| Fukumoto, H; Fukuoka, K; Kato, H; Koh, Y; Koizumi, F; Kuh, HJ; Nakamura, T; Nishio, K; Saijo, N; Suzuki, T; Tamura, T; Usuda, J | 1 |
| Clements, MK; Daoud, SS; Jones, CB; Wasi, S | 1 |
| Akinaga, S; Akiyama, T; Shimizu, M; Sugiyama, K; Tamaoki, T | 1 |
| Abe, S; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, A | 1 |
| Gales, J; Graves, PR; O'Connor, PM; Piwnica-Worms, H; Sausville, EA; Schwarz, JK; Yu, L | 1 |
| Balis, FM; Bauer, K; Figg, WD; Monks, A; Mont, EK; Raffeld, M; Sausville, E; Senderowicz, AM; Sorbara, L; Warren, KE; Wilson, WH | 1 |
| Förstermann, U; Li, H | 1 |
| Sausville, EA; Senderowicz, AM | 1 |
| Akinaga, S; Akiyama, T; Eastman, A; Shimizu, M; Sugiyama, K; Takahashi, R; Tamaoki, T; Yamaguchi, K | 1 |
| Fukumoto, H; Kamiya, Y; Kanzawa, F; Kuh, HJ; Nishio, K; Ohe, Y; Saijo, N; Suzuki, T; Tamura, T; Usuda, J | 1 |
| Abraham, RT; Busby, EC; Karnitz, LM; Leistritz, DF; Sarkaria, JN | 1 |
| Chambers, TC; Drake, RR; Jones, KE; McMasters, RA; Moyer, MP; Pitlyk, K; Saylors, RL; Wilbert, TN | 1 |
| Tsuchida, E; Tsuchida, M; Urano, M | 1 |
| Connelly, JW; Harris, ED; Hose, CD; Monks, A; Sausville, EA; Vaigro-Wolff, A | 1 |
| Andreeff, M; Kitada, S; Reed, JC; Zapata, JM | 1 |
| Akinaga, S; Akiyama, T; Sugiyama, K | 1 |
| Fuse, E; Hashimoto, A; Kobayashi, S; Kuwabara, T; Sato, N; Sugiyama, Y; Tanii, H | 1 |
| Kobayashi, S; Kurata, N; Matsushita, S; Nishi, K; Otagiri, M; Suenaga, A; Watanabe, HH | 1 |
| Abe, S; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, M | 2 |
| Bauer, KS; Figg, WD; Lush, RM; Rudek, MA; Sausville, E; Shih, C | 1 |
| Cory, JG; Somerville, L | 1 |
| Bibb, JA; Biernat, J; Eisenbrand, G; Garnier, M; Greengard, P; Hoessel, R; Leclerc, S; Mandelkow, EM; Marko, D; Meijer, L; Snyder, GL; Wu, YZ | 1 |
| Boise, LH; Dent, P; Grant, S; Tang, L | 1 |
| Clements, MK; Daoud, SS; Jones, CB; Redkar, A | 1 |
| Batova, A; Bridgeman, LJ; Chang, RC; de Wit, E; Diccianni, MB; Kung, FH; Omura-Minamisawa, M; Pullen, JD; Yu, AL; Yu, J | 1 |
| Kuh, HJ; Nakagawa, S; Nishio, K; Saijo, N; Usuda, J; Yamaoka, K | 1 |
| Imabeppu, S; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Nitoh, M | 1 |
| Azuma, A; Huang, P; Li, YX; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L | 1 |
| Senderowicz, AM | 7 |
| Blagosklonny, MV; Dixon, SC; Figg, WD; Robey, R | 1 |
| Fuse, E; Kobayashi, H; Kobayashi, S; Kuramitu, T; Kurata, N; Kuwabara, T; Nishiie, H; Oishi, T; Yasoshima, K | 1 |
| Hsueh, CT; Schwartz, GK; Wu, YC | 1 |
| Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM | 1 |
| Stark, GR; Taylor, WR | 1 |
| Graves, PR; Lovly, CM; Piwnica-Worms, H; Uy, GL | 1 |
| Abe, S; Akinaga, S; Akiyama, T; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, M | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Lehman, T; Lucas, D; Sausville, E; Shinn, C; Willis, CR | 1 |
| Daoud, SS; Meadows, GG; Redkar, AA | 1 |
| Nishio, K | 1 |
| Dai, Y; Dent, P; Grant, S; McInistry, R; Singh, V; Tang, L; Wang, Z; Yu, C | 1 |
| Figg, WD; Krüger, EA | 1 |
| Berger, MS; Hirose, Y; Pieper, RO | 1 |
| Baker, JR; Phelps, E; Utsugi, S; Wang, SH | 1 |
| Cortes, J; Madden, TL; Newman, RA; Smith, JA | 1 |
| Feijoo, C; Gilbert, DM; Hall-Jackson, C; Jenkins, D; Leitch, J; Smythe, C; Wu, R | 1 |
| Kaye, SB; Swannie, HC | 1 |
| Grosios, K | 1 |
| Faller, DV; Guo, N; Vaziri, C | 1 |
| Fujita, N; Sato, S; Tsuruo, T | 1 |
| Brown, MK; Eastman, A; Kohn, EA; Livingstone, M; Ruth, ND | 1 |
| Danenberg, KD; Danenberg, PV; Grem, JL; Kao, V; Nguyen, D | 1 |
| Chambers, WH; Erff, ML; Okada, H; Pollack, IF; Witham, TF | 1 |
| Butler, J; Franklin, WA; Makeyev, Y; Vikram, B; Xiao, HH | 1 |
| Cartee, L; Davis, C; Dent, P; Grant, S; Lin, PS; Maggio, S; Sankala, H; Smith, R | 1 |
| Bozko, P; Larsen, AK; Raymond, E; Skladanowski, A | 1 |
| Howard, OM; Kim, HH; Lin, TS; Neuberg, DS; Shipp, MA | 1 |
| Cheson, BD | 1 |
| Hicks, DJ; Paraskeva, C; Playle, LC; Qualtrough, D | 1 |
| Plunkett, W; Sampath, D; Shi, Z | 1 |
| Abe, S; Hashimoto, M; Hosoda, Y; Kitajima, M; Koh, J; Kubota, T; Migita, T | 1 |
| Dai, Y; Dent, P; Grant, S; Landowski, TH; Rosen, ST | 1 |
| Kohn, KW; La Rose, J; Pommier, Y; Takemura, H; Yu, Q; Zhang, H | 1 |
| Ensley, JF; Gutkind, JS; Igishi, T; Kremer, M; Lahusen, T; Leethanakul, C; Patel, V; Quintanilla-Martinez, L; Sausville, EA; Senderowicz, AM | 1 |
| Keating, MJ; Plunkett, W; Yamauchi, T | 1 |
| Blank, DH; Brown, MK; Eastman, A; Gribble, GW; Kohn, EA; Livingstone, M; Rathman, J | 1 |
| Grant, S; Wang, S; Wang, Z | 1 |
| Friedrich, TD; Lehman, JM; Okubo, E | 1 |
| Clay-Farrace, L; Laskey, RA; Pelizon, C; Pines, J; Santamaria, D | 1 |
| Hui, ZG; Li, YX; Wu, JX; Yang, WZ; Yu, ZH | 1 |
| Pruschy, M; Tenzer, A | 1 |
| Sausville, EA | 2 |
| Edelman, MJ; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, AH; Mack, PC | 1 |
| Dent, P; Grant, S; Jia, W; Krystal, G; Rahmani, M; Sausville, EA; Yu, C | 1 |
| Hu, B; Iliakis, G; Khadpe, J; Wang, X; Wang, Y | 1 |
| Fujita, N; Tsuruo, T | 1 |
| Hashimoto, M; Hosoda, Y; Kitajima, M; Koh, J; Koyama, T; Kubota, T; Migita, T | 1 |
| Clarke, PR; Dikovskaya, D; Hutchins, JR | 1 |
| Chan, UP; Chen, GG; Lee, JF; Leung, KL; Wang, SH | 1 |
| Gohda, E; Horio, T; Nagao, T; Sotani, T; Yagi, Y; Yamamoto, I | 1 |
| Conrad, DH; Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Dai, Y; Dent, P; Grant, S | 1 |
| Alemany, C; Ciudad, CJ; Noé, V; Peñuelas, S | 1 |
| Swanton, C | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Gómez-Román, JJ; Gutkind, JS; Li, Y; Montaner, S; Patel, V; Sausville, EA; Sawai, ET; Sodhi, A | 1 |
| Hagenauer, B; Jäger, W; Maier-Salamon, A; Senderowicz, A; Thalhammer, T; Zöllner, P | 1 |
| Asaka, M; Chiba, K; Hashino, S; Imamura, M; Kato, N; Kobayashi, M; Kondo, T; Minami, Y; Minamino, N; Onozawa, M; Suzuki, S; Tanaka, J; Yokoyama, A | 1 |
| De Siervi, A; Facchinetti, MM; Senderowicz, AM; Toskos, D | 1 |
| Cejka, P; Di Pietro, M; Ferrari, S; Jiricny, J; Marra, G; Mojas, N; Stojic, L | 1 |
| Amornphimoltham, P; Benavides, F; Conti, CJ; Gutkind, JS; Molinolo, AA; Patel, V; Sauk, J; Sausville, EA; Sriuranpong, V | 1 |
| Bok, R; Park, JW; Rini, BI; Scott, J; Shaw, V; Small, EJ; Weinberg, V | 1 |
| Krupski, M; Mani, S; O'Guin, K; Okwuaka, C; Parashar, B; Shafit-Zagardo, B; Shankar, SL | 1 |
| Alley, MC; Dasmahapatra, GP; Didolkar, P; Ghosh, S; Roy, KK; Sausville, EA | 1 |
| Desai, AB; Jacobberger, JW; Kinsella, TJ; Loh, T; Sramkoski, RM; Yan, T | 1 |
| Schwartz, GK; Tse, AN | 1 |
| Bhonde, MR; Daniel, PT; Hanski, C; Hanski, ML; Kohno, K; Magrini, R; Moorthy, D; Müller, A; Sausville, EA; Wiegand, P; Zeitz, M | 1 |
| Lam, MH; Rosen, JM | 1 |
| Cao, P; Gronda, M; Hedley, DW; Jacobberger, JW; Pham, NA; Schimmer, AD | 1 |
| Dai, Y; Dent, P; Grant, S; Han, SI; Khanna, P; Mitchell, C; Pei, XY; Rahmani, M | 1 |
| Chuang, VT; Katsuki, M; Nishi, K; Otagiri, M; Suenaga, A | 1 |
| Acharya, MR; Chen, H; Figg, WD; Headlee, D; Kuwabara, T; Messmann, RA; Murgo, AJ; Sausville, EA; Senderowicz, AM; Sparreboom, A; Venzon, DJ | 1 |
| Chuang, VT; Hirono, S; Katsuki, M; Kawahara, K; Nakayama, H; Nishi, K; Otagiri, M; Yamaotsu, N | 1 |
| Cushman, SW; Kondapaka, SB; Sausville, EA; Yver, DR; Zarnowski, M | 1 |
| Gandara, DR; Goldberg, Z; Gumerlock, PH; Gustafsson, MH; Jones, AA; Mack, PC | 1 |
| Comijn, EM; Kamphuis, JA; Peters, GJ; Sigmond, J | 1 |
| Bastians, H; Kienitz, A; Müller, R; Vogel, C | 1 |
| Stern, DF; Tsvetkov, L | 1 |
| Gillespie, DA; Rainey, MD; Zachos, G | 1 |
| Hui, ZG; Li, YX; Yang, WZ; Yu, ZH | 1 |
| Chang, RL; Conney, AH; Hansson, A; Huberman, E; Klemons, S; Lin, Y; Patel, N; Ryan, A; Shih, WJ; Zheng, X | 1 |
| Adamson, AW; Baskaran, R; Beardsley, DI; Brown, KD; Gao, Y; Kim, WJ | 1 |
| Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Aylesworth, C; Baker, SD; Carducci, MA; Davidson, SB; Dees, EC; Donehower, RC; Elza-Brown, K; O'Reilly, S; Rudek, MA | 1 |
| Daoud, SS; Mixter, P; Redkar, A | 1 |
| Dent, P; Grant, S; Hahn, M; Li, W; Rahmani, M; Yu, C | 1 |
| Figg, WD; Fuse, E; Kuwabara, T; Sausville, EA; Sparreboom, A | 1 |
| Cao, JP; Fan, SJ; Luo, JL; Meng, QH; Tong, J; Zhou, LX | 1 |
| Bresnick, E; Eastman, A; Kohn, EA; Levesque, AA | 1 |
| Ferbeyre, G; Mukhopadhyay, UK; Senderowicz, AM | 1 |
| Bartek, J; Fugger, K; Hansen, LT; Helleday, T; Johansson, F; Lukas, J; Lundin, C; Sehested, M; Syljuåsen, RG; Sørensen, CS | 1 |
| Aoki, H; Fujiwara, K; Kanzawa, T; Kondo, S; Kondo, Y; Mills, GB; Takeuchi, H | 1 |
| Blagden, S; de Bono, J | 1 |
| Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Lara, PN; Longmate, J; Mack, PC; Synold, T | 1 |
| Dai, Y; Dent, P; Grant, S; Li, W; Pei, XY; Rahmani, M | 1 |
| Kato, Y; Kusano, H; Nakakura, M; Yamauchi, M | 1 |
| Albanese, C; D'Amico, M; Mani, S; Pestell, RG; Wang, C; Wu, K | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW | 1 |
| Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Dai, Y; Dawson, K; Dent, P; Gilfor, D; Grant, S; Hawkins, W; McKinstry, R; Mitchell, C; Ramakrishnan, V; Roberts, JD; Starkey, J; Yacoub, A | 1 |
| Franklin, RA; Libra, M; McCubrey, JA; Stivala, F | 1 |
| Aladjem, MI; Aune, GJ; Bonner, WM; Furuta, T; Hayward, RL; Kohn, KW; Meng, LH; Pommier, Y; Takemura, H | 1 |
| Mayersohn, M; Tang, H | 1 |
| Caldecott, KW; Gillespie, DA; Jackson, DA; Maya-Mendoza, A; Petermann, E; Zachos, G | 1 |
| Baras, A; Chua, A; Maxhimer, JB; Nguyen, DM; Schrump, DS; Shamimi-Noori, S; Yeow, WS; Ziauddin, MF | 1 |
| Arra, M; Bertona, M; Emanuele, E | 1 |
| Alexandrow, MG; Barkley, LR; Bi, X; Day, T; Liu, P; Nasheuer, HP; Slater, DM; Vaziri, C | 1 |
| Dai, Y; Dent, P; Grant, S; Li, W; Pei, XY | 1 |
| Beaulieu, B; Beelen, AP; Eastman, A; Ernstoff, MS; Johnston, N; Lewis, LD; Olszanski, AJ; Perez, RP; Rhodes, CH | 1 |
| Bastians, H; Hager, C; Vogel, C | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Khanna, P; Pei, XY | 1 |
| Aslanian, AS; Lees, JA; Reinhardt, HC; Yaffe, MB | 1 |
| Bhawal, UK; Kuniyasu, H; Mitani, Y; Nomura, Y; Otsubo, A; Ozawa, K; Sugiyama, M | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| Bauer, KS; Bisacia, S; Dancey, J; Edelman, MJ; Smith, R; Wu, S | 1 |
| Guo, L; Liu, X; Nishikawa, K; Plunkett, W | 1 |
| Aladjem, MI; Conti, C; Pommier, Y; Seiler, JA; Syed, A | 1 |
| Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S | 1 |
| Dai, Y; Dent, P; Grant, S; Harada, H; Lu, J; Pei, XY; Tenorio, S | 1 |
| Chen, XG; Zuo, MX | 1 |
| Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Abe, M; Aoki, N; Kato, Y; Kusano, H; Nakakura, M; Saito, E; Tsutsumi, K; Uosaki, Y; Yamauchi, M | 1 |
| Chen, GG; Lee, TW; Li, M; Mok, TS; Xu, H; Yim, AP; Yip, JH | 1 |
| Cai, Q; Fan, ST; Lao, X; Redpath, JL; Stanbridge, EJ; Wang, XQ | 1 |
| Cavelier, C; Demur, C; Didier, C; Ducommun, B; Galcera, MO; Laurent, G; Manenti, S; Quaranta, M | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Dai, Y; Dent, P; Gilfor, D; Grant, S; Hagan, MP; Hamed, H; Hawkins, W; Mitchell, C; Pei, XY; Roberts, JD; Yacoub, A; Zhang, G | 1 |
| Eastman, A; Fanous, AA; Poh, A; Zhang, WH | 1 |
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA | 1 |
| Castedo, M; Criollo, A; Galluzzi, L; Kroemer, G; Senovilla, L; Vitale, I; Vivet, S | 1 |
| Aguilera, N; Auerbach, A; Burger, AM; D'Costa, AM; Jiang, F; Rapoport, AP; Sands, AM; Sausville, EA; Stass, SA; Zhao, MY; Zhao, XF | 1 |
| Bonner, WM; D'Ambrosio, E; Kumari, D; Nakamura, AJ; Somma, V; Usdin, K | 1 |
| Giordano, A; Lapenna, S | 1 |
| Kuntz, K; O'Connell, MJ | 1 |
| Chen, S; Jackson, DA; Loric, J; Maya-Mendoza, A; Sims, PF; Tang, CW; Zeng, K | 1 |
| Baba, T; Berchuck, A; Cory Barnett, J; Fujii, S; Kondoh, E; Konishi, I; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS; Yamaguchi, K | 1 |
| Cavelier, C; Demur, C; Didier, C; Ducommun, B; Manenti, S; Mansat-De Mas, V; Prade, N; Recher, C | 1 |
| Demidenko, E; Eastman, A; Hou, H; Khan, N; Lariviere, JP; Mupparaju, SP; Swartz, HM | 1 |
| Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA | 1 |
| Bork, U; Dittmar, T; Kuchler, A; Lee, WK; Thévenod, F | 1 |
| Chen, XM; Chen, YD; Li, HF; Liu, HC; Lu, S; Lu, T; Ran, T; Yuan, HL | 1 |
| Kwak, S; Theurkauf, WE; Varmark, H | 1 |
| Bartek, J; Hasvold, G; Lukas, J; Petersen, L; Syljuåsen, RG | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Dent, P; Eulitt, P; Mitchell, C; Park, M; Yacoub, A; Yang, C | 1 |
| Agarwala, SS; Christensen, SD; Frankel, PH; Gandara, DR; Lara, PN; Li, T; Luu, T; Mack, PC; Margolin, KA | 1 |
| Han, DI; Jeong, SJ; Kim, SH; Park, KH; Park, YG; Rhee, YH | 1 |
| Dudgeon, C; Peng, R; Sun, Q; Sun, X; Wang, P; Yu, J; Zhang, L | 1 |
| Kaliyaperumal, S; Patrick, SM; Williams, KJ | 1 |
| Bosset, M; Decrion-Barthod, AZ; Launay, S; Marchini, A; Mougin, C; Nicolier, M; Plissonnier, ML; Prétet, JL; Rommelaere, J | 1 |
| Baxter, BK; DiDone, L; Krysan, DJ; Ogu, D; Schor, S | 1 |
| Lam, MH; Papineni, R; Peddibhotla, S; Rosen, JM; Wei, Z; Zhang, P | 1 |
| Blain, SW; Ye, W | 1 |
| Chen, Y; Chow, JP; Ma, HT; On, KF; Poon, RY | 1 |
| Alers, S; Daubrawa, M; Dieterle, A; Driessen, S; Hoffmann, N; Iftner, T; Lauber, K; Löffler, A; Manns, J; Paasch, F; Schulze-Osthoff, K; Stork, B; Wesselborg, S | 1 |
| Dunleavy, K; Figg, WD; Grant, ND; Jaffe, ES; Janik, JE; Marti, GE; Steinberg, SM; Stetler-Stevenson, M; Tohnya, T; White, T; Wilson, WH | 1 |
| Jung, IL; Kim, SY; Kwon, YW; Park, SG; Sung, JH | 1 |
| Bilardi, RA; Cutts, SM; Evison, BJ; Forrest, RA; Pastuovic, M; Phillips, DR; Pumuye, PP; Sleebs, BE; Watson, KG | 1 |
| Chen, AP; Doroshow, JH; Kummar, S; Nguyen, D; Pommier, Y; Rubinstein, L; Tomaszewski, JE; Voeller, D; Yang, SX; Zajac-Kaye, M | 1 |
| Choy, ML; Lee, JH; Marks, PA; Ngo, L; Venta-Perez, G | 1 |
| Alcántara Hernández, R; García-Sáinz, JA | 1 |
| Fujinaka, Y; Gillespie, DA; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Matsuoka, K; Morita, M; Saeki, H; Sakasai, R; Takata, M; Tuul, M; Yamamoto, K; Yoshinaga, K | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Kayamori, T; Miyamoto, A; Murayama, C; Shimizu, T | 1 |
| Dai, Y; Dent, P; Grant, S; Tang, Y | 1 |
| Jeong, IH; Kim, YM; Pyo, H | 1 |
| Brown, EJ; Schoppy, DW | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Chen, Y; Chow, JP; Poon, RY | 1 |
| Agarwal, A; Agarwal, M; Agarwal, MK; Chakrabarti, A; Glick, A; Gupta, K; Sharma, JP; Wald, DN; Yang, J; Zhang, Y | 1 |
| Chang, J; Di, X; Fan, W; Shen, Y; Sui, M; Zhang, H | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
| Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER | 1 |
| Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M | 1 |
| Feitelson, MA; Lin, N; Liu, B; Wu, G; Xu, L | 1 |
| Davaadelger, B; Maki, CG; Perez, RE; Shen, H | 1 |
| Beeharry, N; Caviston, JP; Rattner, JB; Yen, T | 1 |
| Cabezas-Herrera, J; Fernández-Pérez, MP; Montenegro, MF; Piñero-Madrona, A; Rodríguez-López, JN; Sáez-Ayala, M; Sánchez-del-Campo, L | 1 |
| Sturla, SJ; van Midwoud, PM | 1 |
| Abankwa, D; Bagga, M; Guzmán, C; Kaur, A; Westermarck, J | 1 |
| Biffoni, M; De Majo, M; De Maria, R; di Martino, S; Giannetti, S; Larocca, LM; Morgante, L; Pallini, R; Pelacchi, F; Petricoin, EF; Ricci-Vitiani, L; Runci, D; Signore, M; Stancato, L | 1 |
| Alcántara-Hernández, R; García-Sáinz, JA; Hernández-Méndez, A | 1 |
| Liu, X; Luo, N; Luo, Y; Nie, C; Tong, A; Wang, C; Wei, Y; Yuan, Z; Zhao, X | 1 |
| Jain, A; Jain, R; Jain, S; Kohli, DV | 1 |
| Davey, S; Osorio-Zambrano, WF | 1 |
| Huang, RC; Kimura, K | 1 |
| Biffoni, M; Buccarelli, M; Cappellari, M; De Luca, G; Fanciulli, M; Goeman, F; Melucci, E; Pilozzi, E; Ricci-Vitiani, L; Signore, M | 1 |
| Chen, TY; Huang, BM; Kang, FC; Kuan, TS; Lien, WC; Lin, TC; Sheu, SY; Wang, CY; Yu, CH | 1 |
| Asami, Y; Crump, A; Ōmura, S | 1 |
| Cai, X; Ding, M; Liang, C; Sheng, Y; Weng, XQ; Wu, J | 1 |
| Jain, A; Jain, R; Jain, S; Khatik, R; Veer Kohli, D | 1 |
| Bui, T; Hunt, KK; Keyomarsi, K; Livingston, JA; Mull, BB; Patel, N | 1 |
| Abbas, F; Belot, A; Duquesne, A; Durupt, S; Fauter, M; Georgin-Lavialle, S; Gerfaud-Valentin, M; Giurgea, I; Grateau, G; Henry, T; Hot, A; Jamilloux, Y; Magnotti, F; Malsot, T; Martin, A; Rabilloud, M; Savey, L; Sève, P | 1 |
| Arena, A; Benedetti, R; Cirone, M; Gaeta, A; Gilardini Montani, MS; Romeo, MA | 1 |
| Akter, N; Bochel, A; Crump, MP; Dedi, N; Landin, EJB; Redfield, C; Ryan, SA; Sessions, RB; Taylor, RJ; Williams, C | 1 |
| Balistreri, G; Cattelani, L; Cerullo, V; Del Giudice, G; Federico, A; Fratello, M; Greco, D; Horvath, P; Kinaret, PAS; Kuivanen, S; Lieto, AD; Ojha, R; Pavel, A; Provenzani, R; Saarimäki, LA; Serra, A; Tasnadi, E; Vapalahti, O; Yli-Kauhaluoma, J | 1 |
| Angeles, C; Enzor, LA; Levesque, AA; Pappalardo, RM; Puli, P | 1 |
30 review(s) available for staurosporine and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Potent and specific inhibitors of protein kinase C of microbial origin.
Topics: Alkaloids; Bacteria; Carbazoles; Fungi; Indole Alkaloids; Naphthalenes; Phosphorylation; Polycyclic Compounds; Protein Kinase C; Signal Transduction; Staurosporine | 1990 |
Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.
Topics: Alkaloids; Animals; Carbazoles; Humans; Indole Alkaloids; Protein Kinase C; Staurosporine | 1989 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Topics: Alkaloids; Antineoplastic Agents, Alkylating; Bryostatins; Flavonoids; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Piperidines; Staurosporine; Topoisomerase I Inhibitors | 1998 |
Analogs of staurosporine: potential anticancer drugs?
Topics: Alkaloids; Animals; Antineoplastic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Protein Kinase C; Signal Transduction; Staurosporine | 1998 |
Preclinical and clinical development of cyclin-dependent kinase modulators.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2000 |
Staurosporine analogues - pharmacological toys or useful antitumour agents?
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Protein Kinase C; Staurosporine | 2000 |
UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century?
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Damage; Enzyme Inhibitors; Humans; Staurosporine | 2000 |
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Topics: Alkaloids; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; Piperidines; Retinoblastoma Protein; Signal Transduction; Staurosporine | 2001 |
Regulation of the G2/M transition by p53.
Topics: 14-3-3 Proteins; Alkaloids; Animals; Biomarkers, Tumor; Caffeine; CDC2 Protein Kinase; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Exonucleases; Exoribonucleases; G2 Phase; Humans; Mitosis; Neoplasm Proteins; Phosphorylation; Proteins; Staurosporine; Tumor Suppressor Protein p53 | 2001 |
[CDK inhibitors for therapy of cancer].
Topics: Alkaloids; Animals; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Piperidines; Protein Transport; Staurosporine; Stomach Neoplasms | 2001 |
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Delivery Systems; Enzyme Inhibitors; Flavonoids; Humans; Piperidines; Protein Kinase C; Retinoblastoma Protein; Staurosporine | 2000 |
Protein kinase C inhibitors.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Bryostatins; Clinical Trials as Topic; Drug Resistance, Multiple; Enzyme Activation; Enzyme Inhibitors; Humans; Lactones; Macrolides; Molecular Structure; Oligodeoxyribonucleotides, Antisense; Protein Kinase C; Research Design; Staurosporine; Thionucleotides; Tumor Cells, Cultured | 2002 |
UCN-01 Kyowa Hakko Kogyo Co.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Enzyme Inhibitors; Humans; Protein Kinase C; Staurosporine; Structure-Activity Relationship | 2001 |
The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinases; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Flavonoids; Humans; Neoplasm Proteins; Neoplasms; Piperidines; Signal Transduction; Staurosporine; Transcription, Genetic | 2002 |
Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators.
Topics: Alkaloids; Animals; Antineoplastic Agents; Caffeine; Cell Cycle Proteins; Cell Survival; Combined Modality Therapy; DNA Damage; Drug Synergism; G2 Phase; Humans; Staurosporine; Xanthines | 2003 |
Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Topics: Alkaloids; Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Evaluation, Preclinical; Enzyme Inhibitors; Flavonoids; Humans; National Institutes of Health (U.S.); Piperidines; Staurosporine; United States | 2003 |
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine; Tumor Cells, Cultured | 2003 |
Cell cycle modulators for the treatment of lung malignancies.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin-Dependent Kinases; Enzyme Inhibitors; Genes, Retinoblastoma; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 2003 |
Cell-cycle targeted therapies.
Topics: Animals; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2004 |
Chk1 versus Cdc25: chking one's levels of cellular proliferation.
Topics: Animals; Antineoplastic Agents; cdc25 Phosphatases; Cell Cycle Proteins; Cell Proliferation; Checkpoint Kinase 1; Clinical Trials as Topic; Humans; Mice; Models, Biological; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine | 2004 |
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Topics: Animals; Antineoplastic Agents; Drug Design; Drugs, Investigational; Humans; Staurosporine | 2005 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Staurosporine | 2005 |
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Neoplasms; Piperidines; Purines; Roscovitine; Staurosporine | 2007 |
Cell cycle kinases as therapeutic targets for cancer.
Topics: Animals; Aurora Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA Damage; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retinoblastoma-Like Protein p130; Staurosporine | 2009 |
The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer?
Topics: Antineoplastic Agents; Biological Evolution; Cell Cycle Proteins; Checkpoint Kinase 1; Conserved Sequence; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Drug Delivery Systems; G2 Phase; Genes, cdc; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Replication Protein A; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Species Specificity; Staurosporine | 2009 |
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine | 2018 |
20 trial(s) available for staurosporine and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Topics: Alkaloids; Animals; Antineoplastic Agents; Dogs; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Mice; Mice, Inbred BALB C; Orosomucoid; Protein Binding; Rats; Serum Albumin; Staurosporine; Substrate Specificity | 1998 |
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Topics: Adult; Alkaloids; Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Dogs; Enzyme Inhibitors; Humans; Infusions, Intravenous; Mice; Mice, Nude; Protein Binding; Protein Kinase C; Rats; Staurosporine; Transplantation, Heterologous | 1998 |
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting | 2001 |
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Female; Flow Cytometry; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Staurosporine; Time Factors; Treatment Outcome | 2004 |
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Topics: Antineoplastic Agents; Female; Half-Life; Humans; Infusions, Intravenous; Male; Neoplasms; Orosomucoid; Staurosporine | 2004 |
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2005 |
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase C; Salvage Therapy; Staurosporine; Time Factors | 2005 |
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrial Fibrillation; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Cyclin B; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Deglutition Disorders; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Infections; Male; Middle Aged; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Renal Insufficiency; Staurosporine; Tachycardia; Treatment Outcome; Tumor Suppressor Proteins | 2005 |
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan | 2006 |
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured | 2006 |
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cell Cycle; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Maximum Tolerated Dose; Neoplasms; Predictive Value of Tests; Staurosporine; Tissue Distribution; Treatment Outcome | 2006 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Female; Humans; Male; Middle Aged; Neoplasms; Staurosporine | 2007 |
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan | 2007 |
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prednisone; Staurosporine; Young Adult | 2010 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Cell Cycle; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; Staurosporine; Time Factors; Treatment Outcome | 2012 |
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Middle Aged; Staurosporine; Treatment Outcome; Vidarabine Phosphate | 2011 |
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome | 2013 |
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult | 2013 |
250 other study(ies) available for staurosporine and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Structural basis for Chk1 inhibition by UCN-01.
Topics: Alkaloids; Amino Acid Sequence; Checkpoint Kinase 1; Models, Molecular; Molecular Sequence Data; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Structure-Activity Relationship | 2002 |
Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Binding Sites; Catalytic Domain; Cell Line; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Conformation; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Recombinant Proteins; Spodoptera; Staurosporine; Structure-Activity Relationship | 2003 |
Glucocorticoids increase Ca2+ influx through dihydropyridine-sensitive channels linked to activation of protein kinase C in vascular smooth muscle cells.
Topics: Alkaloids; Animals; Aorta; Calcium; Calcium Channels; Carbazoles; Cell Line; Cell Membrane; Cytosol; Dexamethasone; Indoles; Isradipine; Kinetics; Muscle, Smooth, Vascular; Protein Kinase C; Pyrroles; Rats; Staurosporine | 1992 |
Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors.
Topics: Alkaloids; Animals; Avian Sarcoma Viruses; Brain; Cattle; Cell Line; Chick Embryo; Molecular Structure; Myocardium; Naphthalenes; Oncogene Protein pp60(v-src); Polycyclic Compounds; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Rats; Staurosporine; Structure-Activity Relationship | 1991 |
Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Division; Down-Regulation; ErbB Receptors; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Oncogenes; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1991 |
Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Enzyme Activation; Kinetics; Leukemia, Erythroblastic, Acute; Mice; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1990 |
Comparison of effects of protein kinase C inhibitors on phorbol ester-induced CD4 down-regulation and augmentation of human immunodeficiency virus replication in human T cell lines.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; CD4 Antigens; Cell Line; Down-Regulation; Flow Cytometry; Gene Products, gag; HIV; HIV Antigens; HIV Core Protein p24; Humans; Isoquinolines; Piperazines; Protein Kinase C; Staurosporine; T-Lymphocytes; Tetradecanoylphorbol Acetate; Viral Core Proteins; Virus Replication | 1989 |
UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.
Topics: Alkaloids; Bacteria; Candida albicans; Cell Division; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; HeLa Cells; Humans; Isomerism; Magnetic Resonance Spectroscopy; Molecular Structure; Protein Kinase C; Staurosporine | 1989 |
UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation.
Topics: Alkaloids; Cell Wall; Chromatography, High Pressure Liquid; Culture Media; Fermentation; Hydrogen-Ion Concentration; Isomerism; Microscopy, Electron, Scanning; Protein Kinase C; Soil Microbiology; Staurosporine; Streptomyces | 1989 |
UCN-01, a selective inhibitor of protein kinase C from Streptomyces.
Topics: Alkaloids; Antineoplastic Agents; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Hydrogen-Ion Concentration; Protein Kinase C; Soil Microbiology; Staurosporine; Streptomyces; Tumor Cells, Cultured | 1987 |
Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; DNA, Neoplasm; Humans; Protein Kinase C; Staining and Labeling; Staurosporine; Time Factors; Tumor Cells, Cultured | 1994 |
Researchers gain footholds in the cell cycle.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Humans; Neoplasms; Pentoxifylline; Staurosporine | 1995 |
Effects of insulin, insulin-like growth factor-I, and phorbol esters on neutral cholesteryl esterase activity in cultured rat vascular smooth muscle cells.
Topics: Alkaloids; Animals; Aorta; Carbazoles; Cells, Cultured; Cyclic AMP; Indoles; Insulin; Insulin-Like Growth Factor I; Male; Muscle, Smooth, Vascular; Phenylurea Compounds; Phorbol Esters; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Staurosporine; Sterol Esterase; Sterol O-Acyltransferase; Tetradecanoylphorbol Acetate | 1995 |
Effect of a potent selective protein kinase C inhibitor on histamine release from rat mast cells.
Topics: Alkaloids; Animals; Calcimycin; Histamine Release; Immunoglobulin E; In Vitro Techniques; Mast Cells; Protein Kinase C; Rats; Staurosporine; Tetradecanoylphorbol Acetate | 1993 |
Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells.
Topics: Alkaloids; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Flow Cytometry; Growth Inhibitors; Humans; In Vitro Techniques; Phosphoproteins; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Staurosporine; Time Factors; Tumor Cells, Cultured; Tyrosine | 1993 |
Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line; Dose-Response Relationship, Drug; Humans; Isoenzymes; Lung Neoplasms; Protein Kinase C; Staurosporine; Structure-Activity Relationship; Tumor Cells, Cultured | 1995 |
UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily.
Topics: Alkaloids; Amino Acid Sequence; Animals; Antineoplastic Agents; Brain; Isoenzymes; Molecular Sequence Data; Protein Kinase C; Rabbits; Recombinant Proteins; Staurosporine | 1995 |
Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity.
Topics: Administration, Oral; Alkaloids; Animals; Antineoplastic Agents; Infusions, Intravenous; Injections, Subcutaneous; Mice; Protein Kinase C; Staurosporine | 1994 |
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Topics: Alkaloids; Animals; Cattle; Isoenzymes; Kinetics; Mice; Protein Kinase C; Staurosporine | 1994 |
Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC.
Topics: Alkaloids; Animals; Carbazoles; Cattle; Indole Alkaloids; Isoenzymes; Protein Kinase C; Staurosporine; Substrate Specificity | 1993 |
Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Drug Synergism; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Inbred Strains; Mice, Nude; Mitomycin; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1993 |
Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Topics: Alkaloids; Amino Acid Sequence; Apoptosis; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Activation; Enzyme Inhibitors; Humans; Indoles; Leukemia; Maleimides; Molecular Sequence Data; Protein Kinase C; Protein Serine-Threonine Kinases; Staurosporine; Stem Cells; T-Lymphocytes; Tumor Cells, Cultured | 1995 |
Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Topics: Alkaloids; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Division; Cell Line; Doxorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Fluorescent Dyes; Humans; Indoles; Maleimides; Protein Kinase C; Rhodamine 123; Rhodamines; Staurosporine; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine | 1996 |
UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line.
Topics: Alkaloids; Calcium-Calmodulin-Dependent Protein Kinases; Cell Cycle; Cell Line; Cyclin-Dependent Kinases; DNA, Neoplasm; Enzyme Inhibitors; Histones; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase C; Retinoblastoma Protein; Staurosporine; Tumor Cells, Cultured | 1996 |
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Topics: Alkaloids; Antineoplastic Agents; Burkitt Lymphoma; CDC2 Protein Kinase; Cell Division; Cell Survival; Cisplatin; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Drug Synergism; Flow Cytometry; G2 Phase; Gamma Rays; Genes, p53; Humans; Immunoblotting; Mitotic Index; Mutation; Precipitin Tests; Radiation Dosage; Staurosporine; Tumor Cells, Cultured | 1996 |
Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Brefeldin A; Camptothecin; Cell-Free System; Cyclin B; Cyclin B1; Cyclins; Cycloheximide; Cyclopentanes; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HL-60 Cells; HT29 Cells; Humans; Mutation; Protein Synthesis Inhibitors; Staurosporine; Time Factors; Tumor Suppressor Protein p53 | 1996 |
G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; G1 Phase; Humans; Microtubule-Associated Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Retinoblastoma Protein; RNA, Messenger; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1997 |
7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells.
Topics: Alkaloids; Animals; Antineoplastic Agents; Aphidicolin; CDC2 Protein Kinase; Cell Fractionation; CHO Cells; Cisplatin; Cricetinae; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA Fragmentation; Enzyme Inhibitors; G2 Phase; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; S Phase; Staurosporine; Tumor Suppressor Protein p53 | 1997 |
Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
Topics: Alkaloids; Antineoplastic Agents; Blotting, Western; Cell Membrane; Cell Nucleus; Cytosol; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Humans; Indoles; Isoenzymes; Maleimides; Microscopy, Confocal; Models, Chemical; Protein Kinase C; Protein Kinase C-theta; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Zinc Fingers | 1997 |
7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53.
Topics: Adenocarcinoma; Alkaloids; Apoptosis; Caspase 3; Caspases; CDC2 Protein Kinase; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Enzyme Inhibitors; HL-60 Cells; HT29 Cells; Humans; Lamin Type B; Lamins; Leukemia, Myeloid, Acute; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Synthesis Inhibitors; Serine Proteinase Inhibitors; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Topics: Alkaloids; Blotting, Western; Camptothecin; Cell Cycle Proteins; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Protein Kinase C; S Phase; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fibrosarcoma; Fluorouracil; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Protein Kinase C; Staurosporine; Tumor Stem Cell Assay | 1997 |
Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.
Topics: Alkaloids; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Enzyme Activation; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Isoenzymes; Protein Kinase C; Protein Kinase C-alpha; Staurosporine; Up-Regulation | 1997 |
Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bryostatins; Cytarabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endopeptidases; Enzyme Inhibitors; HL-60 Cells; Humans; Lactones; Macrolides; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine | 1997 |
Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Topics: Adenocarcinoma; Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1997 |
Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urine.
Topics: Alkaloids; Antineoplastic Agents; Chromatography, High Pressure Liquid; Fluorescence; Humans; Sensitivity and Specificity; Staurosporine | 1998 |
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA-Binding Proteins; Down-Regulation; Drug Administration Schedule; Drug Synergism; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Fluorouracil; Gene Expression; Humans; Protein Kinase C; Retinoblastoma-Binding Protein 1; Staurosporine; Stomach Neoplasms; Thymidylate Synthase; Transcription Factor DP1; Transcription Factors; Tumor Cells, Cultured | 1998 |
Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C.
Topics: Alkaloids; Animals; Apoptosis; Benzimidazoles; Cell Death; Cell Size; Cell Survival; Cells, Cultured; DNA; Enzyme Inhibitors; Flow Cytometry; Male; Nucleic Acid Conformation; Phenotype; Protein Kinase C; Rats; Rats, Inbred F344; Staurosporine; Thapsigargin; Thymus Gland | 1998 |
Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Enzyme Inhibitors; Female; HeLa Cells; Humans; Protein Kinase C; Radiotherapy Dosage; Spheroids, Cellular; Staurosporine; Tumor Stem Cell Assay; Uterine Cervical Neoplasms | 1998 |
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Drug Synergism; Female; Genes, p53; Humans; Mutagenesis; Ovarian Neoplasms; Recombinant Proteins; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Drug Synergism; Enzyme Inhibitors; G2 Phase; Protein Kinase C; Staurosporine | 1996 |
Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Camptothecin; Catalase; Cell Differentiation; Cell Line; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Granulomatous Disease, Chronic; Humans; Hydrogen Peroxide; Leukemia; Membrane Glycoproteins; Monocytes; NADPH Oxidase 2; NADPH Oxidases; Neoplasm Proteins; Neutrophils; NF-kappa B; Pyrrolidines; Reactive Oxygen Species; Staurosporine; Thiocarbamates; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
Topics: Alkaloids; Alkenes; Amino Acid Sequence; Animals; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Mice; Molecular Sequence Data; Nuclear Proteins; Polyenes; Protein-Tyrosine Kinases; Pyrones; Staurosporine; Tumor Cells, Cultured | 1998 |
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
Topics: Alkaloids; Androstadienes; Antigens, Nuclear; Ataxia Telangiectasia; Camptothecin; Cell Cycle; DNA Damage; DNA Helicases; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; DNA-Activated Protein Kinase; DNA-Binding Proteins; Etoposide; Humans; Ku Autoantigen; Nuclear Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Replication Protein A; Staurosporine; Tumor Cells, Cultured; Wortmannin | 1999 |
Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cells, Cultured; Dogs; Haplorhini; Humans; Injections, Intravenous; Liver; Male; Metabolic Clearance Rate; Mice; Mice, Inbred Strains; Orosomucoid; Protein Binding; Rats; Rats, Sprague-Dawley; Serum Albumin; Species Specificity; Staurosporine | 1999 |
Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell-Free System; Cyclin B; Cyclin B1; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mitosis; Nocodazole; Phosphoprotein Phosphatases; Phosphorylation; Proteins; Skin Neoplasms; Staurosporine; Tumor Cells, Cultured; Tyrosine | 1999 |
Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Coloring Agents; Electrophoresis, Agar Gel; Enzyme Inhibitors; Glioma; Humans; In Situ Nick-End Labeling; Protein Kinase C; Staurosporine; Time Factors; Trypan Blue; Tumor Cells, Cultured | 1999 |
p120(ctn) acts as an inhibitory regulator of cadherin function in colon carcinoma cells.
Topics: Alkaloids; alpha Catenin; Benzoquinones; beta Catenin; Binding Sites; Cadherins; Catenins; Cell Adhesion Molecules; Cell Aggregation; Cytoskeletal Proteins; Delta Catenin; DNA Primers; DNA, Complementary; Electrophoresis; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genistein; HT29 Cells; Humans; Kidney; Lactams, Macrocyclic; Membrane Glycoproteins; Mucin-1; Naphthalenes; Phosphoproteins; Quinones; Rifabutin; Staurosporine; Trans-Activators; Transfection | 1999 |
Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01.
Topics: Alkaloids; Animals; Antineoplastic Agents; Dogs; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Staurosporine; Tissue Distribution; Transplantation, Heterologous | 1999 |
Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Caspase Inhibitors; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Neoplasm Proteins; Nuclear Proteins; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Staurosporine; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine).
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Drug Resistance, Neoplasm; G1 Phase; Humans; Lung Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Staurosporine; Tumor Cells, Cultured | 1999 |
Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; DNA Repair; DNA Replication; DNA-Binding Proteins; Endonucleases; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Proteins; Staurosporine; Tumor Cells, Cultured; Xeroderma Pigmentosum; Xeroderma Pigmentosum Group A Protein | 1999 |
RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Inhibitors; G1 Phase; Genes, p53; Genes, Retinoblastoma; Growth Inhibitors; Humans; Lung Neoplasms; Phosphorylation; Retinoblastoma Protein; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cisplatin; Drug Interactions; Enzyme Inhibitors; Flow Cytometry; Humans; Staurosporine; Tumor Cells, Cultured | 1999 |
UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent.
Topics: Alkaloids; Antineoplastic Agents; Breast; Breast Neoplasms; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Female; G1 Phase; Growth Inhibitors; Humans; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Staurosporine; Tumor Suppressor Protein p53 | 1999 |
Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells.
Topics: Alkaloids; Antineoplastic Agents; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Lung Neoplasms; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Staurosporine; Tumor Cells, Cultured | 2000 |
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cattle; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Endothelium, Vascular; G2 Phase; Humans; S Phase; Staurosporine; Tumor Cells, Cultured | 2000 |
G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Line, Transformed; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; G1 Phase; Growth Inhibitors; Humans; Microtubule-Associated Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
[Antineoplastic effect of novel agents, UCN-01 on human tumor cells transplanted in nude mice].
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Staurosporine; Stomach Neoplasms | 1999 |
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
Topics: Alkaloids; Antineoplastic Agents; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; Cloning, Molecular; DNA Damage; Dose-Response Relationship, Radiation; G2 Phase; HeLa Cells; Humans; Membrane Proteins; Models, Biological; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Serine; Staurosporine; Time Factors | 2000 |
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Topics: Aged; Alkaloids; Antineoplastic Agents; B-Lymphocytes; Drug Resistance, Neoplasm; Humans; Lymph Nodes; Lymphoma, B-Cell; Male; Neoplasm Staging; Protein Kinase C; Staurosporine; T-Lymphocytes; Tissue Distribution | 2000 |
Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene.
Topics: Alkaloids; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Drug Interactions; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Promoter Regions, Genetic; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Rats; RNA, Messenger; Staurosporine; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2000 |
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Drug Synergism; Female; G2 Phase; Genes, p53; Humans; In Situ Nick-End Labeling; Mitomycin; Protein Kinases; S Phase; Staurosporine; Tumor Cells, Cultured | 2000 |
Activation-induced apoptosis of peripheral lymphocytes treated with 7-hydroxystaurosporine, UCN-01.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Culture Media; fas Receptor; Humans; Lymphocyte Activation; Lymphocytes; Receptors, Interleukin-2; Staurosporine; Time Factors | 1999 |
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
Topics: Alkaloids; Antineoplastic Agents; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; G2 Phase; Humans; Inhibitory Concentration 50; K562 Cells; Models, Biological; Phosphorylation; Phosphoserine; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Radiation-Sensitizing Agents; Signal Transduction; Staurosporine | 2000 |
Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Butyrates; Camptothecin; Caspase 3; Caspases; Cell Survival; Colonic Neoplasms; Drug Interactions; Ganciclovir; Humans; Membrane Proteins; Paclitaxel; Peptide Hydrolases; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Simplexvirus; Staurosporine; Thymidine Kinase; Transfection; Tumor Cells, Cultured | 2000 |
Synergistic cytotoxicity between a protein kinase C inhibitor, UCN-01, and monoclonal antibody to the epidermal growth factor receptor on MDA-468 cells.
Topics: Alkaloids; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Mice; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1997 |
UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Death; Drug Synergism; Humans; Mitotic Index; Protein Kinase C; Staurosporine; Thiotepa; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
Topics: Alkaloids; Apoptosis; Carrier Proteins; DNA Fragmentation; DNA-Binding Proteins; Enzyme Inhibitors; Flavonoids; Humans; In Situ Nick-End Labeling; Kinetics; Leukemia, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Transcription Factors; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2000 |
Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein.
Topics: Algorithms; Alkaloids; Animals; Antineoplastic Agents; Humans; Indicators and Reagents; Injections, Intravenous; Linear Models; Male; Models, Biological; Orosomucoid; Protein Binding; Rats; Rats, Sprague-Dawley; Staurosporine | 2000 |
Characterization of a binding site of UCN-01, a novel anticancer drug on alpha-acid glycoprotein.
Topics: Alkaloids; Antineoplastic Agents; Binding, Competitive; Orosomucoid; Progesterone; Propranolol; Staurosporine; Ultracentrifugation; Warfarin | 2000 |
[Sensitivity of UCN-01 lies in the balance of CDK 2 kinase and p21].
Topics: Alkaloids; Animals; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Mice; Mice, Nude; Neoplasm Transplantation; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2000 |
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Topics: Alkaloids; Calibration; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; Protein Kinase C; Reproducibility of Results; Saliva; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Staurosporine | 2000 |
Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to apoptosis induced by 7-hydroxystaurosporine.
Topics: Alkaloids; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cathepsins; CDC2 Protein Kinase; Cell Cycle; Coumarins; Cyclin B; Cyclin B1; Cysteine Proteinase Inhibitors; Cytochrome c Group; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Leukemia L1210; Mice; Oligopeptides; Protein Kinase C; Sensitivity and Specificity; Staurosporine; Tumor Cells, Cultured | 2000 |
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Topics: Adenosine Triphosphate; Alkaloids; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Calcium-Calmodulin-Dependent Protein Kinases; CDC2 Protein Kinase; Cyclin B; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Drugs, Chinese Herbal; Enzyme Inhibitors; Flavonoids; Glycogen Synthase Kinase 3; Glycogen Synthase Kinases; Indoles; Inhibitory Concentration 50; Mice; Molecular Structure; Neostriatum; Nerve Tissue Proteins; Phosphoproteins; Phosphorylation; Phosphothreonine; Piperidines; Staurosporine; tau Proteins | 2001 |
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cytarabine; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; Mitochondria; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells | 2000 |
UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Neoplasm Proteins; Protein Kinase C; Staurosporine; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Staurosporine; Thymidylate Synthase; Tumor Cells, Cultured | 2000 |
In vitro sensitivity of T-cell lymphoblastic leukemia to UCN-01 (7-hydroxystaurosporine) is dependent on p16 protein status: a Pediatric Oncology Group study.
Topics: Alkaloids; Antineoplastic Agents; Carrier Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Gene Deletion; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia-Lymphoma, Adult T-Cell; Phosphorylation; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
A computational model for quantitative analysis of cell cycle arrest and its contribution to overall growth inhibition by anticancer agents.
Topics: Alkaloids; Antineoplastic Agents; Cell Cycle; Cell Division; Computer Simulation; HL-60 Cells; Humans; Jurkat Cells; Kinetics; Lung Neoplasms; Models, Biological; Probability; Reproducibility of Results; Software; Staurosporine | 2000 |
The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs.
Topics: Alkaloids; Animals; Antineoplastic Agents; Area Under Curve; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Rate; Hemodynamics; Infusions, Intravenous; Male; Staurosporine | 2000 |
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Leukemia, Myeloid, Acute; S Phase; Staurosporine; Tumor Cells, Cultured | 2001 |
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine | 2001 |
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Formazans; Humans; Immunoblotting; Male; Prostatic Neoplasms; Signal Transduction; Staurosporine; Tetradecanoylphorbol Acetate; Tetrazolium Salts; Transfection; Tumor Cells, Cultured | 2001 |
Pharmacokinetics, distribution, metabolism and excretion of.
Topics: Alkaloids; Animals; Antineoplastic Agents; Bile; Dogs; Enzyme Inhibitors; Feces; Male; Protein Kinase C; Rats; Rats, Sprague-Dawley; Staurosporine; Tissue Distribution | 2001 |
UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation.
Topics: Acetylcysteine; Alkaloids; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; DNA-Binding Proteins; Down-Regulation; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Glycoproteins; Humans; Protein Biosynthesis; Staurosporine; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding.
Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Alkaloids; Amino Acid Sequence; cdc25 Phosphatases; Cell Cycle Proteins; Cytoplasm; Fatty Acids, Unsaturated; HeLa Cells; Humans; Molecular Sequence Data; Protein Binding; Staurosporine; Tyrosine 3-Monooxygenase | 2001 |
UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; CDC2-CDC28 Kinases; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA, Neoplasm; Drug Resistance, Neoplasm; G1 Phase; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Staurosporine; Transplantation, Heterologous | 2001 |
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Multiple; Genes, bcl-2; Humans; Interleukin-4; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Prednisone; Proto-Oncogene Proteins c-bcl-2; Spleen; Staurosporine; Thymus Gland; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2001 |
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
Topics: Alkaloids; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Bromodeoxyuridine; Camptothecin; Cell Division; Colony-Forming Units Assay; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Staurosporine; Topoisomerase I Inhibitors; Topotecan | 2001 |
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Butadienes; Caspases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Flavonoids; HL-60 Cells; Humans; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Nitriles; Staurosporine; Tumor Cells, Cultured; U937 Cells | 2001 |
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Biological Assay; Blood Proteins; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Neovascularization, Pathologic; Protein Binding; Rats; Rats, Sprague-Dawley; Staurosporine; Suramin; Triazoles | 2001 |
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Topics: Alkaloids; Antineoplastic Agents, Alkylating; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; Drug Synergism; Enzyme Inhibitors; G2 Phase; Glioblastoma; Humans; Mitosis; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Papillary; Cell Survival; Drug Resistance; Humans; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Thyroid Neoplasms; Tumor Cells, Cultured; Vitamin D | 2001 |
Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma.
Topics: Alkaloids; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Humans; Reference Standards; Sensitivity and Specificity; Spectrometry, Fluorescence; Staurosporine | 2001 |
Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing.
Topics: Alkaloids; Animals; Aphidicolin; Ataxia Telangiectasia; Caffeine; Cell Fractionation; Cell Line; Cell Separation; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Replication; Enzyme Inhibitors; Flow Cytometry; Humans; Hydroxyurea; Immunoblotting; Microscopy, Fluorescence; Nucleic Acid Synthesis Inhibitors; Phosphodiesterase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; Replication Origin; S Phase; Staurosporine | 2001 |
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adenoviridae; Alkaloids; Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Caffeine; Carcinogens; CDC2-CDC28 Kinases; Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA; DNA Replication; DNA-Binding Proteins; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; Genes, Dominant; Humans; Immunoblotting; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Alkaloids; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Transplantation, Heterologous | 2002 |
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.
Topics: Alkaloids; Breast; Camptothecin; cdc25 Phosphatases; Cell Cycle Proteins; Cell Death; Cells, Cultured; Cyclin A; Cyclin B; DNA Damage; Enzyme Inhibitors; Female; G1 Phase; Genes, cdc; Humans; Irinotecan; Kinetics; Mitosis; Protein Serine-Threonine Kinases; S Phase; Staurosporine; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Deoxyribonucleotides; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Drug Combinations; Enzyme Inhibitors; Floxuridine; Genes, p53; Humans; Lung Neoplasms; Polymerase Chain Reaction; RNA, Messenger; Staurosporine; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model.
Topics: Alkaloids; Animals; Antigens, Neoplasm; Apoptosis; Brain Neoplasms; Cancer Vaccines; Cell Communication; Dendritic Cells; Drug Administration Schedule; Enzyme Inhibitors; Glioma; Gliosarcoma; Rats; Staurosporine; Tumor Cells, Cultured; Vaccination | 2002 |
7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines.
Topics: Adenocarcinoma; Alkaloids; Flow Cytometry; G2 Phase; Gamma Rays; Humans; Lung Neoplasms; Mutation; Radiation-Sensitizing Agents; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Combined Modality Therapy; Humans; Membrane Potentials; Mitochondria; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Radiation, Ionizing; Staurosporine; Transfection; Tumor Stem Cell Assay; U937 Cells | 2002 |
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Cell Cycle; Colonic Neoplasms; Etoposide; Humans; Staurosporine; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Alkaloids; Antineoplastic Agents; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Staurosporine | 2002 |
Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines.
Topics: Alkaloids; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; G2 Phase; Humans; Radiation-Sensitizing Agents; Staurosporine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Topics: Alkaloids; CDC2-CDC28 Kinases; cdc25 Phosphatases; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Damage; Enzyme Activation; Enzyme Inhibitors; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Vidarabine | 2002 |
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Topics: Alkaloids; Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Estrogens; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Topics: Alkaloids; Apoptosis; Benzamides; Bone Marrow Cells; CDC2 Protein Kinase; Cell Adhesion; Cell Cycle; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Free Radical Scavengers; Humans; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melphalan; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Syndecan-1; Syndecans; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Checkpoint Kinase 1; Checkpoint Kinase 2; Colonic Neoplasms; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Gamma Rays; Humans; Mitosis; Phosphorylation; Precipitin Tests; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Topics: 3T3 Cells; Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin D3; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Flow Cytometry; G1 Phase; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Inhibitory Concentration 50; Kinetics; Mice; Mice, Nude; Neoplasm Transplantation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; S Phase; Staurosporine; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.
Topics: Alkaloids; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cells, Cultured; Cyclophosphamide; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Combinations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Staurosporine; Ultraviolet Rays | 2002 |
A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Carbazoles; Cell Cycle; Cell Division; Cisplatin; DNA; DNA Damage; Dose-Response Relationship, Drug; Female; Flow Cytometry; G2 Phase; Genes, p53; Humans; Immunoblotting; Indoles; Models, Chemical; Mutation; Protein Binding; S Phase; Staurosporine; Time Factors; Tumor Cells, Cultured | 2002 |
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bryostatins; Carrier Proteins; Caspases; Cytarabine; Cytochrome c Group; Drug Synergism; Enzyme Activation; Gene Deletion; HL-60 Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lactones; Leukemia, Myeloid; Macrolides; Maleimides; Mitochondrial Proteins; Mutation; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
Negative regulation of mitotic promoting factor by the checkpoint kinase chk1 in simian virus 40 lytic infection.
Topics: Alkaloids; Animals; Caffeine; Cell Line; Checkpoint Kinase 1; Chlorocebus aethiops; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Mitosis; Nocodazole; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Simian virus 40; Staurosporine; Viral Proteins | 2003 |
Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1.
Topics: Alkaloids; Cell Cycle Proteins; Checkpoint Kinase 1; DNA Damage; DNA Replication; Enzyme Inhibitors; HeLa Cells; Humans; Microinjections; Mitosis; Mutation; Nuclear Proteins; Protein Kinases; Recombinant Fusion Proteins; Staurosporine | 2003 |
[Abrogation of radiation-induced G2 arrest and radiosensitization by 7-hydroxystaurosporine (UCN-01) in human nasopharyngeal carcinoma cell line].
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; G2 Phase; Genes, p53; Humans; Mutation; Nasopharyngeal Neoplasms; Protein Kinase C; Radiation-Sensitizing Agents; Staurosporine | 2003 |
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cisplatin; Drug Synergism; Humans; Lung Neoplasms; Phosphorylation; Staurosporine; Tumor Cells, Cultured | 2003 |
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Benzoquinones; Caspases; Drug Synergism; HL-60 Cells; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Rifabutin; Staurosporine; U937 Cells | 2003 |
An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells.
Topics: Alkaloids; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Proteins; Cell Line, Transformed; Cell Survival; Checkpoint Kinase 1; Enzyme Inhibitors; Fibroblasts; G2 Phase; Humans; Phosphodiesterase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; RNA, Small Interfering; Staurosporine | 2003 |
Survival-signaling pathway as a promising target for cancer chemotherapy.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Alkaloids; Animals; Antineoplastic Agents; Blotting, Western; Cell Survival; DNA, Complementary; Drug Design; Enzyme Inhibitors; Gene Expression; HSP90 Heat-Shock Proteins; Humans; Protein Kinase C; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Topotecan; Tumor Cells, Cultured | 2003 |
Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Staurosporine; Tamoxifen | 2003 |
Regulation of Cdc2/cyclin B activation in Xenopus egg extracts via inhibitory phosphorylation of Cdc25C phosphatase by Ca(2+)/calmodulin-dependent protein [corrected] kinase II.
Topics: Amino Acid Sequence; Animals; Azepines; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; CDC2-CDC28 Kinases; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; Cloning, Molecular; Cyclin B; DNA Damage; DNA Replication; Female; G2 Phase; Interphase; Mitosis; Models, Molecular; Molecular Sequence Data; Oocytes; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Pyrroles; Staurosporine; Xenopus laevis; Xenopus Proteins | 2003 |
Induction of colon cancer cell death by 7-hydroxystaurosporine (UCN-01) is associated with increased p38 MAPK and decreased Bcl-xL.
Topics: Apoptosis; bcl-X Protein; Caspase 3; Caspases; Colonic Neoplasms; Dose-Response Relationship, Drug; HT29 Cells; Humans; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Staurosporine; Transcription Factors | 2003 |
Induction by staurosporine of hepatocyte growth factor production in human skin fibroblasts independent of protein kinase inhibition.
Topics: Cyclic AMP; Enzyme Inhibitors; Fibroblasts; Hepatocyte Growth Factor; Humans; Protein Kinase Inhibitors; Skin; Staurosporine; Structure-Activity Relationship | 2003 |
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Humans; Intracellular Membranes; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; Nitriles; Organic Chemicals; Proteoglycans; Staurosporine; Sulfones; Syndecan-1; Syndecans | 2004 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Ligands; Membrane Glycoproteins; Mitochondria; Mitochondrial Diseases; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Staurosporine; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
Topics: Animals; Blotting, Western; Cell Division; Cell Nucleus; CHO Cells; Cloning, Molecular; Cricetinae; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Flow Cytometry; HeLa Cells; Humans; Indoles; K562 Cells; Kinetin; Luciferases; Maleimides; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C; Protein Synthesis Inhibitors; Purines; Retinoblastoma Protein; RNA, Messenger; Roscovitine; Sp1 Transcription Factor; Staurosporine; Tetrahydrofolate Dehydrogenase; Time Factors; Transcription, Genetic; Transfection | 2003 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor.
Topics: Animals; Cell Line, Transformed; GTP-Binding Proteins; Herpesvirus 8, Human; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface; Sarcoma, Kaposi; Staurosporine | 2004 |
Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Bile; Biological Availability; Glucuronides; Kinetics; Liver; Perfusion; Rats; Rats, Mutant Strains; Rats, Wistar; Staurosporine | 2004 |
Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex.
Topics: Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA Replication; Enzyme Inhibitors; HeLa Cells; Humans; Infrared Rays; Leupeptins; Phosphorylation; Recombinant Proteins; S-Phase Kinase-Associated Proteins; Staurosporine; Ubiquitin; Ultraviolet Rays | 2004 |
UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Genes, ras; HCT116 Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA, Messenger; Staurosporine; Transcriptional Activation; Transfection; Up-Regulation | 2004 |
Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells.
Topics: Antineoplastic Agents; CDC2-CDC28 Kinases; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin A; Cyclin B; Cyclin-Dependent Kinase 2; Cytarabine; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; HT29 Cells; Humans; Protein Kinases; S Phase; Staurosporine | 2004 |
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase.
Topics: Ataxia Telangiectasia Mutated Proteins; Base Pair Mismatch; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA; DNA Damage; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; G2 Phase; Histones; Humans; Methylation; Methylnitronitrosoguanidine; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Replication Protein A; Signal Transduction; Staurosporine; Tumor Suppressor Proteins | 2004 |
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Enzyme Activation; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mouth Mucosa; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin; Staurosporine; Time Factors | 2004 |
UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Nervous System Neoplasms; Neuroblastoma; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2004 |
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoblotting; Lung Neoplasms; Male; Phosphorylcholine; Prostatic Neoplasms; Signal Transduction; Staurosporine; Time Factors | 2004 |
CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Topics: Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Base Pair Mismatch; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Staurosporine; Thioguanine; Tumor Suppressor Proteins | 2004 |
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Replication; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; G2 Phase; HCT116 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Mitosis; S Phase; Staurosporine; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2004 |
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Colonic Neoplasms; Cyclin-Dependent Kinases; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; STAT3 Transcription Factor; Staurosporine; Trans-Activators; Tumor Cells, Cultured | 2005 |
The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice.
Topics: Animals; Anticarcinogenic Agents; Antigens; Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspases; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Nucleus; DNA; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Glutathione; Humans; Isothiocyanates; Male; Membrane Potentials; Mice; Mice, SCID; Microscopy, Fluorescence; Mitochondria; Mitosis; Neoplasm Transplantation; Neoplasms; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Staurosporine; Sulfoxides; Thiocyanates; Time Factors; Tyrosine | 2004 |
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Topics: Acute Disease; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid; MAP Kinase Kinase 4; MAP Kinase Signaling System; Membrane Potentials; Methionine; Mitochondria; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; U937 Cells | 2005 |
Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.
Topics: Amino Acid Sequence; Antineoplastic Agents; Circular Dichroism; Hydrogen-Ion Concentration; Molecular Sequence Data; N-Acetylneuraminic Acid; Orosomucoid; Protein Binding; Staurosporine; Tryptophan | 2004 |
Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein.
Topics: Amino Acid Sequence; Binding, Competitive; Chromatography, High Pressure Liquid; Humans; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Orosomucoid; Photoaffinity Labels; Protein Binding; Protein Conformation; Staurosporine; Time Factors; Trypsin | 2005 |
7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Cell Membrane; Cytosol; Dose-Response Relationship, Drug; Enzyme Activation; Glucose; Glucose Transporter Type 4; Immunoblotting; Insulin; Male; Microsomes; Monosaccharide Transport Proteins; Muscle Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Serine; Staurosporine; Subcellular Fractions; Threonine | 2004 |
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Staurosporine; Tumor Suppressor Protein p53 | 2004 |
Combinations of 5-fluorouracil with UCN-01 or staurosporine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Separation; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Humans; Inhibitory Concentration 50; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine; Time Factors | 2004 |
The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Separation; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Mitosis; Nocodazole; Protein Kinase Inhibitors; Signal Transduction; Spindle Apparatus; Staurosporine; Time Factors; Topoisomerase Inhibitors; Transgenes | 2005 |
Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Topics: Ataxia Telangiectasia Mutated Proteins; Caffeine; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin B; DNA Damage; DNA-Binding Proteins; Doxorubicin; Enzyme Activation; G2 Phase; Humans; Mitosis; Nocodazole; Phosphorylation; Polo-Like Kinase 1; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Serine; Signal Transduction; Staurosporine; Threonine; Tumor Suppressor Proteins | 2005 |
Chk1-dependent S-M checkpoint delay in vertebrate cells is linked to maintenance of viable replication structures.
Topics: Animals; Antineoplastic Agents; Aphidicolin; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Chickens; DNA Replication; Gene Targeting; Mitosis; Nocodazole; Nucleic Acid Conformation; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Staurosporine | 2005 |
[Abrogation effect of UCN-01 on radiation-induced G2 phase arrest of tumor cells and its mechanism].
Topics: Adenocarcinoma; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; G2 Phase; Genes, p53; Humans; Lung Neoplasms; Mutation; Nasopharyngeal Neoplasms; Particle Accelerators; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2005 |
Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells.
Topics: Alkaloids; Antineoplastic Agents; Benzophenanthridines; Capsaicin; Carboxylesterase; Carcinogens; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Macrophages; Models, Chemical; Phenanthridines; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Time Factors | 2005 |
Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2.
Topics: Base Pair Mismatch; Cell Division; Cell Nucleus; Cells, Cultured; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA Methylation; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; G2 Phase; Humans; Immunoblotting; Immunoprecipitation; Methylnitronitrosoguanidine; MutS Homolog 2 Protein; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Staurosporine; Subcellular Fractions; Time Factors | 2005 |
Indifferently pursued or unowned drugs: who should lead where companies do not tread?
Topics: Antineoplastic Agents; Drug Industry; Humans; Neoplasms; Orphan Drug Production; Protein Kinase Inhibitors; Staurosporine | 2005 |
Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Epithelial Cells; Female; Genes, p53; Humans; Staurosporine; Topotecan; Tumor Cells, Cultured | 2004 |
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspases; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Genes, Dominant; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Kinase 1; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sirolimus; Staurosporine; Time Factors; U937 Cells | 2005 |
Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration.
Topics: BRCA1 Protein; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioblastoma; Humans; Protein Kinase C; RNA, Messenger; Staurosporine | 2005 |
Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.
Topics: Camptothecin; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; DNA Damage; Female; G2 Phase; Humans; Irinotecan; Repressor Proteins; S Phase; Staurosporine; Transcriptional Activation; Tumor Suppressor Protein p53 | 2005 |
RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Topics: Antibiotics, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Diploidy; DNA Damage; DNA-Binding Proteins; Doxorubicin; Fibroblasts; G2 Phase; Gene Expression; Gene Silencing; Genes, cdc; Genes, p53; Humans; Male; Mutation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; RNA Interference; RNA, Catalytic; RNA, Neoplasm; RNA, Small Interfering; Staurosporine; Transfection; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
Topics: Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; Chromosomal Proteins, Non-Histone; DNA Damage; DNA Replication; DNA-Binding Proteins; DNA, Single-Stranded; Histones; Humans; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Purines; Replication Protein A; RNA, Small Interfering; Roscovitine; Staurosporine; Tumor Suppressor Protein p53 | 2005 |
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sirolimus; Staurosporine; TOR Serine-Threonine Kinases | 2005 |
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cytochromes c; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Glycogen Synthase Kinase 3; Humans; JNK Mitogen-Activated Protein Kinases; Methionine; Multiple Myeloma; Phosphorylation; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Staurosporine; Trans-Activators | 2005 |
Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes.
Topics: Animals; Humans; Liposomes; Male; Orosomucoid; Protein Binding; Rats; Rats, Sprague-Dawley; Staurosporine | 2005 |
A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspase 8; Caspase 9; Caspases; Cell Survival; Collagen Type XI; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Staurosporine; Survivin; Transfection | 2005 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
Topics: Apoptosis; Benzamides; Breast Neoplasms; Cell Death; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Staurosporine | 2005 |
Two targets are better than one. Promising combination therapy to treat breast cancer.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Staurosporine | 2005 |
p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
Topics: Aphidicolin; Apoptosis; Chromosome Breakage; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Damage; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; HCT116 Cells; Histones; Humans; In Situ Nick-End Labeling; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; S Phase; Staurosporine; Tumor Suppressor Protein p53 | 2006 |
On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding.
Topics: Animals; Blood Proteins; Humans; Metabolic Clearance Rate; Models, Biological; Protein Binding; Protein Kinase Inhibitors; Rats; Species Specificity; Staurosporine | 2006 |
Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Checkpoint Kinase 1; Chickens; Chromosomes; DNA Replication; DNA, Single-Stranded; Fluorescent Antibody Technique, Indirect; Humans; Immunoblotting; Kinetics; Protein Kinase Inhibitors; Protein Kinases; RNA, Small Interfering; S Phase; Staurosporine | 2006 |
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-kappa B; Staurosporine; Tumor Cells, Cultured; Valproic Acid | 2006 |
7-Hydroxystaurosporine may have a therapeutic role in treatment-resistant depression by inhibition of calcium/calmodulin-dependent protein kinase II.
Topics: Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Depression; Drug Resistance; Humans; Protein Kinase Inhibitors; Staurosporine; Treatment Failure | 2007 |
The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism.
Topics: cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Chromatin; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 2; DNA-Binding Proteins; HeLa Cells; Humans; Minichromosome Maintenance Complex Component 7; Minichromosome Maintenance Proteins; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Protein Kinases; S Phase; Staurosporine | 2006 |
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Topics: Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Multiple Myeloma; Phosphorylation; Protein Kinases; RNA Interference; Staurosporine | 2006 |
Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Calcium-Binding Proteins; CDC2 Protein Kinase; Cell Cycle Proteins; Doxorubicin; Drug Synergism; G2 Phase; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Mad2 Proteins; Microtubule-Associated Proteins; Mitosis; Neoplasm Proteins; Protein Serine-Threonine Kinases; Repressor Proteins; Spindle Apparatus; Staurosporine; Survivin | 2007 |
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Topics: Cell Death; Drug Synergism; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jurkat Cells; Leukemia; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Protein Prenylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Staurosporine; Transfection; Tumor Cells, Cultured; U937 Cells | 2007 |
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; G2 Phase; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Nude; Mitosis; Neoplasms, Experimental; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase C; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ultraviolet Rays | 2007 |
UCN-01 (7-hydroxystaurosporine) induces apoptosis and G1 arrest of both primary and metastatic oral cancer cell lines in vitro.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; G1 Phase; Humans; Mouth Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2007 |
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; G2 Phase; Histones; Humans; Leukemia, Myeloid, Acute; Phenanthrenes; Phenanthridines; Phosphorylation; Staurosporine; Topoisomerase II Inhibitors | 2007 |
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses.
Topics: Camptothecin; DNA; DNA Damage; DNA Replication; Histones; HT29 Cells; Humans; Models, Biological; Protein Transport; Replication Origin; S Phase; Staurosporine | 2007 |
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Benzamides; Blotting, Western; Drug Synergism; Enzyme Inhibitors; Humans; Immunoprecipitation; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Multiple Myeloma; Phosphorylation; Protein Conformation; Protein Kinase C; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Staurosporine; Subcellular Fractions | 2007 |
AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.
Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Genes, p53; Glioma; Humans; Poly(ADP-ribose) Polymerases; Signal Transduction; Staurosporine; Tumor Suppressor Protein p53; Tyrphostins | 2007 |
Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Liposomes; Male; Orosomucoid; Particle Size; Protein Binding; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Staurosporine; Transition Temperature | 2008 |
Increased inducible nitric oxide synthase in lung carcinoma of smokers.
Topics: Adult; Aged; Aged, 80 and over; Caspase 3; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Nitrosamines; S-Nitroso-N-Acetylpenicillamine; Smoking; Staurosporine | 2008 |
p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest.
Topics: Caffeine; cdc25 Phosphatases; Cell Line; Checkpoint Kinase 1; Checkpoint Kinase 2; Down-Regulation; G2 Phase; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Staurosporine; Tumor Suppressor Protein p53 | 2007 |
G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; cdc25 Phosphatases; Cell Division; Cell Line, Tumor; Colony-Forming Units Assay; G2 Phase; Humans; Leukemia, Myeloid, Acute; Mitosis; Nocodazole; Staurosporine; U937 Cells | 2008 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
Topics: Blotting, Western; Cell Death; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; MAP Kinase Kinase 1; Protein Kinase Inhibitors; Staurosporine | 2008 |
DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA Primers; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Staurosporine | 2008 |
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays | 2008 |
Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Enzyme Inhibitors; HCT116 Cells; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Protein Kinases; Pyridines; RNA, Small Interfering; Staurosporine; Transfection; Tumor Suppressor Protein p53 | 2008 |
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; Drug Synergism; Female; Flow Cytometry; G1 Phase; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sirolimus; Staurosporine; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2009 |
The role of DNA damage response pathways in chromosome fragility in Fragile X syndrome.
Topics: Aphidicolin; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Chromosome Breakage; Chromosome Fragile Sites; Chromosome Fragility; DNA Damage; DNA Repair; DNA-Binding Proteins; Floxuridine; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Knockdown Techniques; Histones; Humans; Male; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrones; Staurosporine; Tumor Suppressor Proteins | 2009 |
Interaction with checkpoint kinase 1 modulates the recruitment of nucleophosmin to chromatin.
Topics: Animals; Cell Line; Checkpoint Kinase 1; Chickens; Chromatin; Chromatin Immunoprecipitation; DNA Damage; Electrophoresis, Gel, Two-Dimensional; Gene Knockout Techniques; HeLa Cells; Humans; Models, Biological; Nuclear Proteins; Nucleophosmin; Protein Binding; Protein Kinases; Proteome; Signal Transduction; Staurosporine; Ultraviolet Rays | 2009 |
Targeting slow-proliferating ovarian cancer cells.
Topics: Antineoplastic Agents; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Ovarian Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2010 |
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Child; Chromosome Aberrations; DNA Damage; Flow Cytometry; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinases; RNA Interference; Signal Transduction; Staurosporine | 2009 |
Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Electron Spin Resonance Spectroscopy; Female; Mice; Mice, Inbred C3H; Neoplasms; Oxygen; Staurosporine | 2009 |
Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cadmium; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Division; Cells, Cultured; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin B; DNA Damage; DNA-Binding Proteins; G2 Phase; Kidney Tubules, Proximal; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Reactive Oxygen Species; Signal Transduction; Staurosporine; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
Topics: Benzodiazepinones; Binding Sites; Biocatalysis; Checkpoint Kinase 1; Drug Design; Ligands; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Tertiary; Pyrazoles; Staurosporine; Structure-Activity Relationship; Thiophenes; Urea | 2010 |
A role for Chk2 in DNA damage induced mitotic delays in human colorectal cancer cells.
Topics: Animals; Caffeine; Checkpoint Kinase 1; Checkpoint Kinase 2; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Damage; Drosophila; G2 Phase; Gene Knockout Techniques; HCT116 Cells; Humans; Mitosis; Protein Kinases; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine | 2010 |
p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors.
Topics: Cell Cycle; Cell Death; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Genes, p53; HCT116 Cells; Humans; Neoplasms; Nervous System Neoplasms; Protein Kinases; Radiation, Ionizing; Staurosporine; Tumor Suppressor Protein p53 | 2010 |
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Topics: Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Drug Synergism; Enzyme Activation; Histones; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Protein Kinases; Signal Transduction; Staurosporine; Thiophenes; Urea | 2010 |
Protein kinase C βII and δ/θ play critical roles in bone morphogenic protein-4-stimulated osteoblastic differentiation of MC3T3-E1 cells.
Topics: 3T3 Cells; Animals; Bone Morphogenetic Protein 4; Cell Differentiation; Isoenzymes; Mice; Osteoblasts; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-delta; Protein Kinase C-theta; Protein Kinase Inhibitors; Staurosporine; Vascular Endothelial Growth Factor A | 2010 |
PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Staurosporine; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition.
Topics: Amino Acid Sequence; Animals; Base Pair Mismatch; Cell Line; Cell Line, Tumor; DNA; DNA Damage; DNA Mismatch Repair; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; HeLa Cells; Humans; Immunoblotting; Mice; Molecular Sequence Data; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Serine; Signal Transduction; Spodoptera; Staurosporine | 2011 |
Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyrates; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Female; HeLa Cells; Human papillomavirus 16; Human papillomavirus 18; Humans; Mice; Mice, Nude; Papillomavirus Infections; Staurosporine; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antifungal Agents; Candida albicans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Saccharomyces cerevisiae; Staurosporine; Sulfonamides | 2011 |
The DNA damage effector Chk1 kinase regulates Cdc14B nucleolar shuttling during cell cycle progression.
Topics: Blotting, Western; Cell Cycle; Cell Line; Cell Nucleolus; Checkpoint Kinase 1; Chromosomal Proteins, Non-Histone; Chromosomes, Human; DNA Damage; Dual-Specificity Phosphatases; Genomic Instability; HeLa Cells; Humans; Immunoblotting; Immunoprecipitation; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Staurosporine | 2011 |
Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caffeine; Camptothecin; Cell Cycle Proteins; Cell Differentiation; Cell Survival; Cells, Cultured; Cerebral Cortex; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA-Binding Proteins; Female; Genes, p53; Genomic Instability; Neurons; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Staurosporine; Tumor Suppressor Proteins | 2011 |
Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01.
Topics: Animals; Cell Cycle Proteins; Cell Survival; Cytokinesis; DNA Damage; G2 Phase; Gamma Rays; HCT116 Cells; HeLa Cells; Humans; Mice; Mitosis; NIH 3T3 Cells; Protein Kinase Inhibitors; Spindle Apparatus; Staurosporine | 2011 |
Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1.
Topics: Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-X Protein; Caspase 9; Cell Line, Tumor; Cytochromes c; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-bcl-2; Staurosporine | 2011 |
Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction.
Topics: Animals; Apoptosis; Biological Transport; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Dual Specificity Phosphatase 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperplasia; Liver-Specific Organic Anion Transporter 1; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; RNA Interference; Staurosporine; Taurochenodeoxycholic Acid; Time Factors; Transfection; Tunica Intima; Up-Regulation | 2011 |
M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Topics: Animals; Anthraquinones; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cattle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Histones; Humans; Mitosis; Permeability; Phosphorylation; Poly-ADP-Ribose Binding Proteins; Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Staurosporine; Structure-Activity Relationship | 2011 |
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Checkpoints; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Repair; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Staurosporine; Time Factors; Topotecan; Tumor Suppressor Protein p53 | 2011 |
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 1; DNA Damage; Drug Resistance; Fibroblasts; Foreskin; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoblotting; Male; Mice; Protein Kinases; Quinolines; Quinuclidines; RNA Interference; Spleen; Staurosporine; Thiophenes; Urea; Vorinostat | 2011 |
Roles of phosphoinositide-dependent kinase-1 in α1B-adrenoceptor phosphorylation and desensitization.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Calcium; Chlorocebus aethiops; COS Cells; Cricetinae; Intracellular Space; Mutation; Norepinephrine; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptors, Adrenergic, alpha-1; Staurosporine | 2012 |
ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Nucleus; Checkpoint Kinase 1; Chickens; Cytoprotection; DNA Breaks, Double-Stranded; Fanconi Anemia Complementation Group D2 Protein; Fluorouracil; Histones; Lymphoma, B-Cell; Mutation; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Recombinational DNA Repair; Signal Transduction; Staurosporine; Time Factors | 2012 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Bone morphogenetic protein (BMP)-4 and BMP-7 suppress granulosa cell apoptosis via different pathways: BMP-4 via PI3K/PDK-1/Akt and BMP-7 via PI3K/PDK-1/PKC.
Topics: Animals; Apoptosis; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Cattle; Cells, Cultured; Chromones; Enzyme Inhibitors; Female; Granulosa Cells; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Staurosporine | 2012 |
Enhancing CHK1 inhibitor lethality in glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzamides; Benzimidazoles; Checkpoint Kinase 1; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase 4; Medulloblastoma; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Protein Kinases; Radiation-Sensitizing Agents; src-Family Kinases; Staurosporine; Tumor Cells, Cultured | 2012 |
Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines.
Topics: Celecoxib; Cell Line, Tumor; Checkpoint Kinase 1; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; G2 Phase; Humans; Mitosis; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Staurosporine; Sulfonamides; Tumor Stem Cell Assay | 2012 |
Chk'ing p53-deficient breast cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Checkpoint Kinase 1; Female; Humans; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea | 2012 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe.
Topics: Apoptosis; Cell Cycle Checkpoints; Checkpoint Kinase 1; DNA Damage; Gene Expression Regulation; Genomic Instability; HCT116 Cells; HeLa Cells; Humans; Kinesins; M Phase Cell Cycle Checkpoints; Mitosis; Protein Kinases; Pyrimidines; Radiation, Ionizing; RNA, Small Interfering; Staurosporine; Thiones | 2012 |
ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway.
Topics: Acute Disease; Adenosine; Adenosine Triphosphate; Antibiotics, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Caffeine; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Comet Assay; DNA Damage; Doxorubicin; HEK293 Cells; Humans; Leukemia, Myeloid; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Thioinosine; Tumor Suppressor Protein p53 | 2012 |
G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Chemoradiotherapy; DNA Fragmentation; Female; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Humans; Microtubules; Paclitaxel; Prohibitins; Radiation, Ionizing; Staurosporine; Tumor Cells, Cultured; Vincristine | 2012 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Checkpoint Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Liver Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Tumor Suppressor Protein p53 | 2013 |
Two 4N cell-cycle arrests contribute to cisplatin-resistance.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cisplatin; Cyclin A; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; DNA Damage; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; RNA, Small Interfering; Staurosporine; Tetraploidy; Tumor Suppressor Protein p53 | 2013 |
Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Centromere; Checkpoint Kinase 1; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Deoxycytidine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; G2 Phase Cell Cycle Checkpoints; Gemcitabine; HeLa Cells; Humans; Kinetochores; Mitosis; Protein Kinases; S Phase Cell Cycle Checkpoints; Staurosporine; Topoisomerase II Inhibitors | 2013 |
Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Activation; Female; Gene Silencing; Humans; Melanoma; Methotrexate; Methylation; Mice; Myosin Heavy Chains; Myosin Type V; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 2C; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.
Topics: Antineoplastic Agents, Alkylating; Cell Survival; Chromatography, High Pressure Liquid; Colonic Neoplasms; DNA Adducts; DNA Repair; DNA Repair Enzymes; Drug Synergism; HT29 Cells; Humans; Sesquiterpenes; Spectrometry, Mass, Electrospray Ionization; Spiro Compounds; Staurosporine | 2013 |
ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays.
Topics: Cell Line, Tumor; Colony-Forming Units Assay; Humans; Staurosporine; Tumor Cells, Cultured | 2014 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Protein Array Analysis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proteomics; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Small Molecule Libraries; Staurosporine; Temozolomide; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cricetinae; Indazoles; Metalloproteases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Staurosporine; Sulfonamides | 2014 |
Caspase-9 mediates Puma activation in UCN-01-induced apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Fibroblasts; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Mice, Nude; Mitochondrial Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2014 |
Coated chitosan nanoparticles encapsulating caspase 3 activator for effective treatment of colorectral cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Caspase 3; Chitosan; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Enzyme Activation; Formazans; Humans; Nanoparticles; Particle Size; Polymethacrylic Acids; Rabbits; Staurosporine; Tetrazolium Salts | 2015 |
Chk1 Activation Protects Rad9A from Degradation as Part of a Positive Feedback Loop during Checkpoint Signalling.
Topics: Bleomycin; Cell Cycle Checkpoints; Cell Cycle Proteins; Checkpoint Kinase 1; DNA Damage; Enzyme Activation; Feedback, Physiological; HeLa Cells; Humans; Immunoprecipitation; Leupeptins; Models, Biological; Phosphorylation; Polyubiquitin; Proteasome Endopeptidase Complex; Protein Kinases; Protein Stability; Proteolysis; RNA, Small Interfering; Signal Transduction; Staurosporine; Ubiquitination | 2015 |
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01.
Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine | 2016 |
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2016 |
7-hydroxy-staurosporine, UCN-01, induces DNA damage response, and autophagy in human osteosarcoma U2-OS cells.
Topics: Autophagy; Bone Neoplasms; Cell Line, Tumor; DNA Damage; Humans; Osteosarcoma; Staurosporine | 2018 |
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Staurosporine; Tretinoin | 2019 |
Minicapsules encapsulating nanoparticles for targeting, apoptosis induction and treatment of colon cancer.
Topics: Animals; Apoptosis; Capsules; Caspase 3; Cell Line, Tumor; Cell Survival; Chitosan; Colonic Neoplasms; DNA Fragmentation; Folic Acid; Mice; Mice, Inbred C57BL; Nanoparticles; Staurosporine; Xenograft Model Antitumor Assays | 2019 |
Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cytostatic Agents; Female; G1 Phase; Humans; Mice; Mice, Nude; Staurosporine | 2020 |
Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Juvenile; Behcet Syndrome; Case-Control Studies; Child; Child, Preschool; Cryopyrin-Associated Periodic Syndromes; Familial Mediterranean Fever; Female; Fever; Fever of Unknown Origin; Hereditary Autoinflammatory Diseases; Humans; Immunologic Tests; Inflammasomes; Interleukin-1beta; Lupus Erythematosus, Systemic; Male; Mevalonate Kinase Deficiency; Middle Aged; Monocytes; Protein Kinase Inhibitors; Pyrin; Pyroptosis; Sensitivity and Specificity; Sepsis; Staurosporine; Still's Disease, Adult-Onset; Young Adult | 2021 |
DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.
Topics: Cell Line; Cell Proliferation; Cells, Cultured; Checkpoint Kinase 1; DNA Damage; Herpesvirus 8, Human; Humans; Leukocytes, Mononuclear; Lymphoma, Primary Effusion; Phthalazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Staurosporine; Tumor Suppressor Protein p53; Virus Replication | 2022 |
The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Humans; Orosomucoid; Protein Binding; Protein Domains; Staurosporine | 2021 |
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.
Topics: A549 Cells; Antiviral Agents; Computational Biology; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Giant Cells; Humans; Pyrimidines; SARS-CoV-2; Staurosporine | 2022 |
p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Damage; DNA, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; Staurosporine; Topoisomerase I Inhibitors | 2022 |